Advertisement
Advertisement
U.S. Markets close in 2 hrs 39 mins
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1600-0.0099 (-5.83%)
As of 03:55PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1699
Open0.1699
BidN/A x N/A
AskN/A x N/A
Day's Range0.1590 - 0.1699
52 Week Range0.1200 - 0.4950
Volume46,474
Avg. Volume141,954
Market Cap15.788M
Beta (5Y Monthly)-1.74
PE Ratio (TTM)5.16
EPS (TTM)0.0310
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

    Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC ("Donohoe") for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market. Silo Pharma hopes to gain additional exposure and access to a wider base of retail and institutional investor

  • GlobeNewswire

    Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

    U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammationEnglewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore licensed homing peptide. The novel homing peptide can be used for enhanced targeting of therapeutic

  • GlobeNewswire

    Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

    Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Eric Weisblum, CEO of Silo Pharma stated “The commencement of Novel Ketamine loaded Z-Pods is a pivotal advancement for administering Ket

Advertisement
Advertisement